People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ansun Biopharma, Inc. | — | Pharma | Series C | $195.1M | $3.5B | 2010 |
Mikael Havluciyan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mikael Havluciyan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| MICHAEL CHANG | 1 | 13 |
| KAREN LIU | 1 | 4 |
| Nancy Chang | 1 | 4 |
| Allen Chao | 1 | 2 |
| Michael Chao | 1 | 2 |
| Dave Chenn | 1 | 2 |
| MARK ATTEBURY | 1 | 1 |
| Michael Havluciyan | 1 | 1 |
| Ron Moss | 1 | 1 |
| AIMIN WU | 1 | 1 |
| YI SHI | 1 | 1 |
| DONALD PAYNE | 1 | 1 |
| Yining Zhao | 1 | 1 |
| Shi Yi | 1 | 1 |
| RONALD MOSS | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.